Janney Montgomery Scott LLC Has $6.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Janney Montgomery Scott LLC reduced its holdings in Regeneron Pharmaceuticals by 55.1%, leaving it with 12,590 shares valued at approximately $6.61 million.
• Regeneron’s recent quarterly earnings showed an EPS of $12.89, significantly above the consensus estimate of $8.43, with revenues of $3.68 billion, representing a 3.6% year-over-year increase.
• The company announced a quarterly dividend of $0.88 per share, translating to an annualized yield of 0.6% with a payout ratio of 8.87%.

Janney Montgomery Scott LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 55.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,590 shares of the biopharmaceutical company's stock after selling 15,452 shares during the quarter. Janney Montgomery Scott LLC's holdings in Regeneron Pharmaceuticals were worth $6,610,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Marietta Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 30.2% in the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after purchasing an additional 2,501 shares during the period. Sepio Capital LP raised its position in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after purchasing an additional 842 shares during the period. Founders Capital Management LLC raised its position in shares of Regeneron Pharmaceuticals by 7.0% in the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after purchasing an additional 538 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 3.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after purchasing an additional 955 shares during the period. Finally, KBC Group NV raised its position in shares of Regeneron Pharmaceuticals by 9.4% in the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after purchasing an additional 12,793 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $600.00 on Monday. The firm's 50-day simple moving average is $572.12 and its 200 day simple moving average is $566.55. The company has a market cap of $63.59 billion, a price-to-earnings ratio of 15.12, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the company earned $11.56 EPS. The firm's quarterly revenue was up 3.6% on a year-over-year basis. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, September 27th. Citigroup reaffirmed a "buy" rating and set a $650.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Jefferies Financial Group boosted their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a research report on Wednesday, August 27th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.